Article
Synergistic effects of mTOR inhibitors with VEGFR3 inhibitors on the interaction between TSC2-mutated cells and lymphatic endothelial cells.
Science China. Life sciences - 1 Jun 2025
Wang Hanghang, Hu Danjing, Cheng Chongsheng, Zhang Xiaoxin, Liu Junya, Tian Xinlun, Zhang Hongbing, Xu Kai-Feng
Abstract excerpt
Lymphangioleiomyomatosis (LAM) is a rare neoplastic disease affecting the lung, kidney, and lymphatic system with a molecular mechanism of tuberous sclerosis complex 2 (TSC2) mutations. Vascular endothelial growth factor D (VEGF-D), a ligand for vascular endothelial growth factor receptor 3 (VEGFR3), is a diagnostic biomarker of LAM and is associated with lymphatic circulation abnormalities. This study explored...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.